Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $536.46M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 1.92M
Average 4.86M
Returns on capital
Wave Life Sciences Ltd. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.8%
avg -91.8%
ROIC
-39.0%
avg -78.7%
ROA
-32.0%
avg -47.5%
Analysis
ROA is currently the strongest return metric at -32.0% versus its period average of -47.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Paul Bolno | President, Chief Executive Officer & Director | USD 1.35M | 52 | 275.52K | 0.14% |
Kyle Moran | Chief Financial Officer & Principal Accounting Officer | USD 864.68K | 55 | 134.38K | 0.07% |
Chandra Vargeese | Chief Technology Officer | USD 836.61K | 65 | 408.25K | 0.21% |
Christopher Francis | Chief Strategy Officer | USD 736.94K | 48 | — | — |
Gregory L. Verdine | Founder & Director | USD 49.38K | 67 | 64.00K | 0.03% |
Erik Ingelsson | Chief Scientific Officer | — | — | 87.86K | 0.05% |
Hsiu-Chiung Yang | Senior Vice President of Translational Medicine | — | — | — | — |
Sridhar Vaddeboina | Senior Vice President of Chemistry, Manufacturing & Controls | — | — | — | — |
Katie Sullivan | Senior Director of Corporate Communications | — | — | — | — |
Daryn Lewis | Senior Vice President & Head of Human Resources | — | — | — | — |
Kate Rausch | Vic President of Corporate Affairs & Investor Relations | — | — | — | — |
Linda Rockett | Senior Vice President & General Counsel | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$82.55M
Sells
38
$13.48M
Net Transaction Value
+$69.07M
Net buying
Most Active
Francis Chris
11 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 12, 26Aug 12, 2026 | Rawcliffe Adrian Direct | Sell | $67.2K$67,183.00 |
| Aug 11, 26Aug 11, 2026 | Tan Aik Na Direct | Sell | $2.6K$2,596.32 |
| Aug 11, 26Aug 11, 2026 | TAKANASHI KEN Direct | Sell | $23.2K$23,222.64 |
| Aug 11, 26Aug 11, 2026 | Wagner Heidi L Direct | Sell | $42.1K$42,070.00 |
| Mar 30, 26Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $6.3M$6,312,091.50 |
| Mar 27, 26Mar 27, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $16M$16,046,855.89 |
| Mar 26, 26Mar 26, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $30M$30,024,621.48 |
| Mar 26, 26Mar 26, 2026 | RA CAPITAL MANAGEMENT, L.P. Indirect | Buy | $2.2M$2,240,809.12 |
| Feb 26, 26Feb 26, 2026 | Francis Chris Direct | Sell | $229.4K$229,410.00 |
| Feb 26, 26Feb 26, 2026 | Francis Chris Direct | Sell | $270.2K$270,182.60 |
1–10 of 43
Summary
Insiders reported 5 buys worth $82.55M and 38 sells worth $13.48M over the last 12 months. That adds up to net buying of $69.07M. Francis Chris was the most active insider with 11 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A13 analysts |
| Revenue | N/A | N/A | +127.1% | +53.3% (5yr)9 analysts |
| Net Income | N/A | N/A | N/A | N/A9 analysts |
| EBIT | N/A | N/A | N/A | N/A9 analysts |
Analysis
Recent growth has been strongest in Revenue at +127.1% over three years. Forward estimates point to Revenue at +53.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Wave Life Sciences Ltd. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about WVE's management, answered from reported figures.
Who manages WVE?
Wave Life Sciences Ltd. (WVE) lists 12 active executives. The top listed executive is Chandra Vargeese, Chief Technology Officer.
Are WVE insiders buying or selling?
Recent insider activity shows net buying of $129.79M.
Continue the stock analysis
Jump to another research area for this company.